Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Investor Presentation (July 2019)
22 slides from Emvision Medical Devices's investor presentation, Jul 25, 2019
Slide 1: Investor Presentation
www.emvision.com.au For personal use only INVESTOR PRESENTATION
Slide 2: Medical Imaging Innovation
MEDICAL IMAGING INNOVATION For personal use only Microwave imaging is a truly innovative imaging modality that has disruptive implications for diagnostics, monitoring and the delivery of care in the future XRAY ULTRASOUND CT MRI + PET ELECTROMAGNETIC MICROWAVE 1895 1950’s 1960’s 1980’s NON-DESTRUCTI
Slide 3: Investment highlights
For personal use only PRE- LARGE HIGHLY LEAD CLINICAL ADDRESSABLE CREDENTIALED PRODUCT EVIDENCE MARKETS MANAGEMENT Lead product in development is Underlying technology is a result of Opportunity to penetrate the multi-billion Management and board with significant designed to be a portable, safe over
Slide 4: Product Pipeline
For personal use only PRODUCT Device Discovery Preclinical Research & Healthy Ethics Pilot Pivotal Regulatory Clearance & PIPELINE & Concept Prototype Human Trials Clearance Clinical Trial Clinical Trial Commercialisation BRAIN SCANNER Identify and monitor Q4 2019 2020 stroke and traumatic brain inj
Slide 5: 1st Application: Stroke & Traumatic Brain Injury
1ST APPLICATION STROKE & For personal use only TRAUMATIC BRAIN INJURY Stroke is the second leading cause of death world wide with 1 in 6 people having a stroke in their lifetime 1 Traumatic Brain Injury (TBI) is the most frequent cause of death and disability worldwide 2 There are effective treatmen
Slide 6: Typical Patient Journey and Timeline
TYPICAL PATIENT JOURNEY AND TIMELINE EMvision’s opportunity is to bring stoke and traumatic brain injury decision support and monitoring to the patient Stroke Onset For personal use only 15 mins to 2.5 hours < 2.5 hours < 3 hours < 24 hours <24 hours - 3 weeks <3 weeks - 3 years+ Pre-Hospital Triage
Slide 7: EMvision's Brain Scanner
EMVISION’S BRAIN SCANNER For personal use only The Company aims to develop a clinical device that delivers these features FUNCTION Provides reliable identification of blood within the brain to facilitate rapid clinical decision making COST-EFFECTIVE Factoring in both cost differential and life PORTA
Slide 8: Technology Overview
TECHNOLOGY OVERVIEW For personal use only Array of antennas send pulses of low-power electromagnetic waves into the head Waves penetrate tissue in a non-ionizing and harmless manner and get scattered based on the electrical properties of tissue Sensors in the helmet detect these interactions to iden
Slide 9: Attractive Revenue Model
ATTRACTIVE REVENUE MODEL For personal use only DEVICE SALES DISTRIBUTION Each sale has multiple Future distribution partners purchase equipment, proposed recurring revenue consumables, accessories and spare parts from streams EMvision and on-sell to their network PURCHASING MODELS CONSUMABLES CAPITA
Slide 10: Key Addressable Markets
KEY ADDRESSABLE MARKETS For personal use only North America 48,000 Ambulances Europe 6,000 Hospitals 60,000 Ambulances China 15,000 Hospitals 30,000 Hospitals SECONDARY MARKETS: Aged Care Australia Rural / Remote Cruise Ships 5,200 Ambulances Military Sport 1,300 Hospitals Humanitarian www.emvision.
Slide 11: Partners & Collaborators
PARTNERS & COLLABORATORS For personal use only Awarded EMvision a $2.6M CRC-P non-dilutive Developer of EMvision’s IP, CRC-P partner, and GE Healthcare is the $19 billion healthcare business cash grant, over three years, in Dec’17. Australia's most successful commercialisation of GE (NYSE:GE) and a
Slide 12: Keysight Collaboration
KEYSIGHT COLLABORATION The strategic collaboration with Keysight Technologies (NYSE: KEYS) will concentrate on engineering VNA units into a highly integrated form factor with the intention of reducing the overall size of EMvision’s brain scanner system For personal use only VNA CLINICAL HOSPITAL AMB
Slide 13: Pilot-Clinical Trial Roadmap
PILOT-CLINICAL TRIAL ROADMAP For personal use only Q1-Q2 Q3 Q4 CY 2019 CY 2019 CY 2019 ISO 13485 Clinical unit bill of materials (BOM) Delivery of clinical Certification review, release and procurement trial units to hospital Successful Healthy Human Trials Commence fabrication and Clinical site ini
Slide 14: 2nd Application: Identifying & Monitoring Liver Disease
2nd APPLICATION For personal use only IDENTIFYING & MONITORING LIVER DISEASE Over 1 BILLION people globally have liver disease 1 in 4 people worldwide have a variant known as non-alcoholic fatty liver disease (NAFLD) Approximately 20% of NAFLD cases are classified as non-alcoholic steatohepatitis (N
Slide 15: Early Detection and Monitoring of Liver Disease
EARLY DETECION AND MONITORING OF LIVER DISEASE For personal use only GLOBAL EPIDEMIC FUELED BY ZERO PRACTICAL DIAGNOSTIC THE BENEFITS OF APPLYING OBESITY RATES AND DIABETES AND MONITORING SOLUTIONS EM MICROWAVE IMAGING The prevalence of NAFLD is constantly Invasive, painful and costly Quantify fat i
Slide 16: EMvision Torso Scanner Development
EMVISION TORSO SCANNER DEVELOPMENT EMvision is exploring the feasibility of a non-invasive and cost-effective Torso For personal use only Scanner to identify the severity and monitor the progression of NAFLD and NASH TISSUE CHARACTERISATION PHANTOM FABRICATED Tissue characterisation work to An enhan
Slide 17: Team & Capital Structure
For personal use only TEAM & CAPITAL STRUCTURE www.emvision.com.au 17
Slide 18: Team
TEAM Significant experience developing and commercialising medical devices For personal use only Dr. Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller Chief Executive Officer Executive Chairman Executive Director Clinical Development Advisor Product Design & Former Exec Direc
Slide 19: Clinical Advisory Board
CLINICAL ADVISORY BOARD EMvision has secured advisors with world-leading experience in diagnosing and treating neurological disorders. The composition and Brisbane location of the group has been For personal use only specifically engineered to aid in delivering a successful clinical trial program “
Slide 20: Capital Structure
For personal use only CAPITAL STRUCTURE Current Cash Balance 1 $4.345m Shares on issue 57.5m Total Options on issue 2 7.9m Performance Rights3 6m Market Cap @ $0.39c* 22.4m EV @ $0.39c* $18m 1 - Cash balance @ 30th June 2019. The Company anticipates having access to additional sources of undrawn non
Slide 21: Get in Touch
www.emvision.com.au For personal use only GET IN TOUCH Dr Ron Weinberger Scott Kirkland CEO, EMvision Executive Director, EMvision E: rweinberger@emvision.com.au E: skirkland@emvision.com.au P: 02 8667 5337 P: 02 8667 5337
Slide 22: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by EMvision Medical Devices Limited (“EMvision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
EMvision Medical Devices — Investor Presentation (July 2019) on 6ix